Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Association Analysis of Premature Coronary Artery Disease and Cytochrome P450 2D6 (Cyp2d6) C100t and G1846a Genetic Variants and Haplotypes in Iranian Population Publisher



Bahiraee A1 ; Nejatizadeh A1 ; Farshidi H2 ; Malekzadeh K1 ; Emamgholipour S3 ; Ebrahimi R3, 4 ; Aghabozorgi AS5 ; Yazdany M1 ; Shekari M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  2. 2. Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  3. 3. Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Medical Genetics Research Center, Basic Medical Sciences Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Meta Gene Published:2020


Abstract

Background: Premature coronary artery disease (pCAD) is a heterogeneous disease affected by both genetic and environmental determinants. Cytochrome P450 2D6 (CYP2D6) enzyme plays an important role in the oxidation of drugs and inactivation of reactive species. Therefore, polymorphisms in CYP2D6 may lead to an increased susceptibility to pCAD. Here, we analyzed the association between C100T and G1846A polymorphisms of CYP2D6 gene with pCAD in a south Iranian population. Methods: Men under 45 and women under 55 years old enrolled in this study as 168 pCAD patients and 167 controls. Clinical characteristics of participants were assessed thorough clinical examination. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was applied for C100T and G1846A polymorphisms. Results: The results indicated that the history of smoking and hypertension were significantly associated with the incidence of pCAD (p < .05). However, results showed that allelic frequencies for none of the study polymorphisms in CYP2D6 were different between case and control groups. Furthermore, they were not associated with the risk of pCAD development in the study population. To better diagnosis of the molecular genetic basis of pCAD as a complex disease, this study used two-locus haplotypes of CYP2D6 polymorphisms as novel biomarkers for pCAD for the first time which also did not show a significant result. Conclusion: This study demonstrated no significant association of C100T and G1846A polymorphisms of CYP2D6 with pCAD in the south Iranian population. The possible explanation may be attributed to the differences in dissimilar ethnic, genetic, and environmental backgrounds, and also different sample sizes. © 2020